Introduction: Who Needs Diagnostic Testing for Metastatic Ovarian Cancer

Metastatic ovarian cancer, also known as Stage IV ovarian cancer, occurs when cancer cells have spread from the ovaries or fallopian tubes to distant areas of the body such as the lungs, liver tissue, or fluid surrounding the lungs^[1]. Women should seek diagnostic evaluation when experiencing persistent symptoms that don’t resolve after a few weeks, particularly if they notice ongoing abdominal bloating, feeling full quickly when eating, discomfort in the pelvic area, unexplained weight loss, constant fatigue, back pain, changes in bowel habits such as constipation, or a frequent need to urinate^[5]. Unfortunately, these symptoms often mimic common conditions like hormonal changes during menopause or chronic pelvic conditions such as endometriosis, which makes early recognition challenging^[6].

Because ovarian cancer symptoms are notoriously difficult to spot and can be confused with more common ailments, many women receive their diagnosis at an advanced stage. More than 70 percent of people with ovarian cancer are diagnosed when the disease has already metastasized, meaning the cancer has spread beyond its original location^[4]. The majority of patients—about 75 percent—present with widely metastatic disease within the peritoneal cavity by the time they are diagnosed^[3]. This late-stage presentation contributes significantly to the disease’s high mortality rate.

It’s advisable to consult a doctor promptly if you experience any combination of these warning signs, especially if symptoms persist or worsen over time. Early medical attention can lead to faster diagnostic testing and treatment planning, which may improve outcomes even in advanced cases.

Classic Diagnostic Methods for Identifying Metastatic Ovarian Cancer

Diagnosing metastatic ovarian cancer involves several steps and types of tests. Doctors combine physical examinations with laboratory work and various imaging techniques to confirm the presence of cancer and determine how far it has spread throughout the body.

Physical Examination

The diagnostic process typically begins with a thorough physical examination by your doctor. During this exam, the physician may perform a pelvic examination to feel for abnormal masses or fluid accumulation in the abdomen. The doctor will also check for swelling or tenderness in the pelvic and abdominal regions. While a physical exam alone cannot confirm cancer, it helps identify areas that require further investigation.

Imaging Tests

Imaging plays a crucial role in detecting metastatic ovarian cancer and mapping where the disease has spread. Several types of imaging tests may be used depending on your symptoms and what your doctor needs to see.

Ultrasound, particularly pelvic and transvaginal ultrasound, uses sound waves to create pictures of the ovaries and surrounding organs. This test can help identify suspicious masses on the ovaries or in the pelvis. It’s often one of the first imaging studies performed when ovarian cancer is suspected.

Computed tomography scans, commonly called CT scans, use X-rays to create detailed cross-sectional images of the body. CT scans of the abdomen and pelvis can reveal tumors on the ovaries and show whether cancer has spread to the peritoneum (the lining of the abdominal cavity), lymph nodes, liver, or other abdominal organs. CT imaging helps doctors assess the extent of disease and plan surgical approaches.

Magnetic resonance imaging, or MRI, uses powerful magnets and radio waves to produce detailed images of soft tissues. MRI scans can provide additional information about tumor size and location, particularly when CT findings are unclear or when more detailed images are needed before surgery.

Chest X-rays or CT scans of the chest may be ordered to check whether cancer has spread to the lungs or caused fluid buildup around the lungs, a condition called pleural effusion. When this fluid contains cancer cells, it indicates Stage 4a metastatic disease^[7].

Positron emission tomography, known as PET scans, may be used in some cases. This imaging technique uses a small amount of radioactive material to highlight areas of increased cell activity, which can indicate cancer. PET scans are sometimes combined with CT scans (PET-CT) to provide both functional and structural information about potential cancer sites.

Laboratory Tests

Blood tests are an essential component of ovarian cancer diagnosis. The most commonly used blood test measures a protein called CA-125, which is often elevated in women with ovarian cancer. However, CA-125 levels can also rise due to non-cancerous conditions such as endometriosis, pelvic inflammatory disease, or even menstruation, so an elevated CA-125 alone does not confirm cancer. Despite its limitations, CA-125 testing helps doctors monitor the disease and assess treatment response.

Other blood tests may check your overall health, including kidney and liver function, which is important when planning treatment strategies. Complete blood counts assess red and white blood cells and platelets, which can be affected by advanced cancer or its treatments.

Surgical Diagnosis and Staging

In many cases, definitive diagnosis of metastatic ovarian cancer requires surgery. During a surgical procedure, the surgeon can directly visualize the ovaries, fallopian tubes, and surrounding organs. The surgical team will examine the pelvis and abdominal cavity to identify where cancer has spread. Tissue samples, called biopsies, are taken from suspicious areas and sent to a laboratory where a specialist called a pathologist examines the cells under a microscope to confirm whether they are cancerous and determine what type of ovarian cancer is present.

The exact stage of the cancer often cannot be determined until surgery is performed. During the operation, the surgeon checks where the cancer has spread in the pelvis and abdomen and whether it has reached the lymph nodes. This process, called surgical staging, provides critical information for treatment planning^[14].

Sometimes a less invasive procedure called laparoscopy may be performed first. This involves inserting a thin tube with a camera through small incisions in the abdomen to view the organs and take biopsies. Laparoscopy can help determine whether the cancer can be removed surgically or whether other treatments should be tried first.

Fluid Analysis

If fluid has accumulated in the abdomen (called ascites) or around the lungs (pleural effusion), doctors may remove a sample of this fluid using a needle. The fluid is then examined under a microscope to look for cancer cells. The presence of cancer cells in the fluid helps confirm the diagnosis and stage of metastatic disease. When cancer cells are found in the pleural fluid, it indicates Stage 4a disease^[7].

Diagnostics for Clinical Trial Qualification

Clinical trials test new treatments or combinations of treatments for metastatic ovarian cancer. To participate in a clinical trial, patients must meet specific requirements, which are determined through diagnostic testing. These qualification criteria help ensure that the trial includes appropriate participants and that results can be properly interpreted.

Confirmation of Diagnosis and Stage

Clinical trials require clear documentation of your cancer diagnosis and stage. This typically means having tissue confirmation through biopsy or surgical pathology showing that you have ovarian, fallopian tube, or primary peritoneal cancer. The stage must be documented through imaging studies and surgical findings. Most trials for metastatic disease specifically require confirmation of Stage IV cancer, meaning the disease has spread to distant organs or caused fluid buildup around the lungs or inside the liver^[7].

Genetic and Molecular Testing

Many modern clinical trials require specific genetic or molecular characteristics of your cancer. Genetic testing of tumor tissue can identify mutations or changes in genes such as BRCA1 and BRCA2, which affect how cancer cells respond to certain treatments. Some trials are designed specifically for patients with BRCA mutations, while others may exclude these patients. Testing may also look for other genetic markers that predict treatment response.

Blood tests can also identify inherited genetic mutations that increase cancer risk. If genetic testing reveals a BRCA mutation, patients may be eligible for maintenance medications called PARP inhibitors, which are often part of clinical trial protocols^[11].

Additional molecular testing may examine the tumor for specific proteins or receptors. For example, testing for folate receptor alpha expression can determine eligibility for certain targeted therapies being studied in clinical trials^[11].

Assessment of Disease Extent

Clinical trials often have specific requirements about how much disease is present and where it is located. This is determined through imaging studies such as CT scans, MRI, or PET scans performed shortly before trial enrollment. Some trials may require measurable disease—meaning tumors that can be accurately measured on imaging and tracked over time to assess treatment effectiveness. Others may accept patients with disease that is visible but not easily measured.

The imaging must be recent, typically within a few weeks before starting the trial, to ensure accurate baseline measurements of disease extent.

Performance Status and Overall Health

Clinical trials evaluate your general health and ability to perform daily activities using scales such as the Eastern Cooperative Oncology Group (ECOG) performance status. This assessment, performed by your doctor, helps determine whether you are healthy enough to tolerate the trial treatment. Blood tests checking kidney function, liver function, and blood cell counts are required to ensure that your organs can process and eliminate the study medications safely.

Previous Treatment History

Many clinical trials have specific requirements about what treatments you have or haven’t received previously. Documentation of your treatment history is essential. Some trials are designed for patients who have never received treatment (called first-line therapy), while others are specifically for patients whose cancer has returned or progressed after prior treatments (called recurrent or refractory disease). Your medical records must clearly document what chemotherapy regimens you received, when you received them, and how your cancer responded.

Biomarker Testing

Some clinical trials require testing for specific biomarkers—biological characteristics that can be measured in blood or tissue. Besides genetic mutations, this might include protein levels, immune system markers, or other molecular features. For example, trials testing immunotherapy drugs may require testing to see how many immune cells are present in and around the tumor.